HanBio Therapeutics

Chinese biotechs are encountering investors who appear to have been balking at acquiring their new shares since early September, with one private equity funding scrapped, a re-financing deal reduced a

With the Nasdaq Biotechnology Index (NBI) and the closely watched XBI biotech fund down 13.2% and 18.9%, respectively, so far this year and 20.3% and 43.6% below where they were trading a year ago, ma